FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-								
Estimated average b	uruen							
I hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ABBOT STEWART</u>				2. Issuer Name and Ticker or Trading Symbol Turnstone Biologics Corp. [TSBX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last)	,	rst) BIOLOGICS CO	(Middle) ORP.		3. Date of Earliest Transaction (Month/Day/Year) 10/16/2023							X Officer (give title below) Other (specify below) Chief Scientific Officer				
9310 ATHENA CIRCLE, SUITE 300				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) LA JOLI	LA CA	A	92037								-	_	led by More t	eporting Perso han One Repo		
(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication																
								cate that a trar defense condi					n or written pla	n that is intended	l to	
		Tab	le I - Non-De	erivativ	e Sec	curities	s Ac	quired, Di	sposed o	f, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			е	Execution Date		Date,	e, Transaction Disposed (Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amour Securitie Beneficia Owned F	s Form ally (D) of ollowing (I) (II	orm: Direct o) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code V	Amount	(A) or (D) Price		Transact (Instr. 3 a	ion(s)		msu. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
Derivative Conversion		Date Execution (Month/Day/Year) if any	3A. Deemed Execution Date, if any (Month/Day/Yea	Code	Transaction of Code (Instr. Deriv		ve es d ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (Right to Buy)	\$2.61	10/16/2023		A		45,542		(1)	10/15/2033	Common Stock	45,542	\$0.00	45,542	D		

Explanation of Responses:

1. One fourth (1/4th) of the shares subject to the option award shall vest on October 12, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

/s/ P. Joseph Campisi, Jr., Attorney-in-Fact

10/17/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.